Low prevalence of antibodies and other plasma factors binding to CC chemokines and IL-2 in HIV-positive patients
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Low prevalence of antibodies and other plasma factors binding to CC chemokines and IL-2 in HIV-positive patients. / Meyer, C N; Svenson, M; Schade Larsen, C; Odum, Niels; Skinhøj, Peter; Bendtzen, K.
In: Acta Pathologica Microbiologica et Immunologica Scandinavica, Vol. 108, No. 2, 2000, p. 122-30.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Low prevalence of antibodies and other plasma factors binding to CC chemokines and IL-2 in HIV-positive patients
AU - Meyer, C N
AU - Svenson, M
AU - Schade Larsen, C
AU - Odum, Niels
AU - Skinhøj, Peter
AU - Bendtzen, K
N1 - Keywords: Chemokine CCL3; Chemokine CCL4; Chemokines, CC; HIV Antibodies; HIV Seropositivity; Humans; Immunoglobulin G; Interleukin-2; Macrophage Inflammatory Proteins; Neutralization Tests; Protein Binding
PY - 2000
Y1 - 2000
N2 - Neutralizing cytokine antibodies are found in healthy and diseased individuals, including patients treated with recombinant cytokines. Identification of CCR-5 as co-receptor for HIV has focused interest on CC chemokines and their potential therapeutic use. Chemokine-binding components in plasma of HIV-infected patients were therefore assessed by radioimmunoassay and radioreceptor assay. IgG from 4/505 HIV patients and 9/2000 healthy controls (p>0.05) bound rMIP-1alpha and rMIP-1beta, but not rRANTES. No other plasma factors bound the chemokines. The antibodies inhibited receptor binding of both chemokines. There was no association between presence of antibodies and disease stage or HIV progression rate. Three of 11 patients treated with rIL-2 developed IgG antibodies suppressing cellular binding and growth promotion of rIL-2. Hence, circulating factors, including antibodies MIP-1alpha/MIP-1beta, are uncommon in healthy individuals and HIV patients, and are apparently without prognostic significance. In contrast to earlier reports, IL-2 antibodies were found only in HIV patients treated with rIL-2.
AB - Neutralizing cytokine antibodies are found in healthy and diseased individuals, including patients treated with recombinant cytokines. Identification of CCR-5 as co-receptor for HIV has focused interest on CC chemokines and their potential therapeutic use. Chemokine-binding components in plasma of HIV-infected patients were therefore assessed by radioimmunoassay and radioreceptor assay. IgG from 4/505 HIV patients and 9/2000 healthy controls (p>0.05) bound rMIP-1alpha and rMIP-1beta, but not rRANTES. No other plasma factors bound the chemokines. The antibodies inhibited receptor binding of both chemokines. There was no association between presence of antibodies and disease stage or HIV progression rate. Three of 11 patients treated with rIL-2 developed IgG antibodies suppressing cellular binding and growth promotion of rIL-2. Hence, circulating factors, including antibodies MIP-1alpha/MIP-1beta, are uncommon in healthy individuals and HIV patients, and are apparently without prognostic significance. In contrast to earlier reports, IL-2 antibodies were found only in HIV patients treated with rIL-2.
M3 - Journal article
C2 - 10737457
VL - 108
SP - 122
EP - 130
JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
SN - 0903-4641
IS - 2
ER -
ID: 10617358